

consistent with Elejalde syndrome (neuroectodermal melanolyosomal disorder). *J Neurol* 247:570–572  
 Seabra MC, Mules EH, Hume AN (2002) Rab GTPases, intracellular traffic and disease. *Trends Mol Med* 8:23–30

Address for correspondence and reprints: Dr. Geneviève de Saint Basile, INSERM U429, Hôpital Necker-Enfants Malades, 169 rue de Sevres, 75015 Paris, France. E-mail: sbasile@necker.fr

© 2002 by The American Society of Human Genetics. All rights reserved. 0002-9297/2002/7105-0026\$15.00

Ménasché G, Fischer A, de Sainte Basile G (2002) Griscelli syndrome type 1 and 2. *Am J Hum Genet* 71:1237–1238 (in this issue)

Address for correspondence and reprints: Dr. Marjan Huizing, 10 Center Drive, MSC 1851, Building 10, Room 10C-103, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-1851. E-mail: mhuizing@mail.nih.gov

© 2002 by The American Society of Human Genetics. All rights reserved. 0002-9297/2002/7105-0027\$15.00

*Am. J. Hum. Genet.* 71:1238, 2002

### Reply to Ménasché et al.

*To the Editor:*

It is gratifying to learn that Ménasché et al. (2002 [in this issue]) agree with our analysis of the phenotypic differences between patients with *RAB27A* mutations and those with *MYO5A* mutations. We leave it to *Journal* readers to decide if previous publications have “unequivocally established” these points. We do apologize for the error in table 1, which we recognized and have corrected in an erratum.

Perhaps we could make two additional points. First, Gaucher disease types I, II, and III represent examples of defects in a single gene resulting in different phenotypes, whereas Griscelli/Elejalde syndromes represent examples of defects in two different genes resulting in phenotypes with some similarities. Second, we wonder what nomenclature should be employed for these two disorders. Ménasché et al. continue to use Griscelli syndromes types 1 and 2. However, Griscelli’s original cases exhibited immune deficiency (Griscelli et al. 1978), whereas Elejalde first recognized a distinct, neurologically based disorder (Elejalde et al. 1979). Perhaps Dr. Elejalde should be credited for the accuracy of his ascertainment.

MARJAN HUIZING,<sup>1</sup> Y. ANIKSTER,<sup>2</sup> AND W. A. GAHL<sup>1</sup>  
<sup>1</sup>Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD; and <sup>2</sup>Metabolic Unit, Sheba Medical Center, Tel Hashomer, Israel

### References

- Elejalde BR, Holguin J, Valencia A, Gilbert EF, Molina J, Marin G, Arango LA (1979) Mutations affecting pigmentation in man. I. Neuroectodermal melanolyosomal disease. *Am J Med Genet* 3:65–80  
 Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog C, Prunieras M. (1978) A syndrome associating partial albinism and immunodeficiency. *Am J Med* 65:691–702

*Am. J. Hum. Genet.* 71:1238–1239, 2002

### Family-Based Association Tests Incorporating Parental Genotypes

*To the Editor:*

The report “Parental Genotypes in the Risk of a Complex Disease” (Labuda et al. 2002) gives several interesting examples of how parental genotypes can contribute to children’s disease risk—for example, through maternal effects during pregnancy or paternal effects during spermatogenesis. The authors note that if disease risk depends on parents’ genotypes but not their child’s genotype, then the distribution of genotypes in cases will not differ from the Mendelian expectation given their parents’ genotypes. Hence, the traditional transmission disequilibrium test (TDT) using case-parent trio data will (correctly) not detect any association between individuals’ genotypes and disease. The authors present an example in which the TDT provides no evidence of an association between a variant allele and disease (in fact, the point estimate for the odds ratio is 1.0), whereas a comparison of case subjects’ genotypes to those of population control subjects does provide evidence of association (estimated odds ratio = 3.4). The authors then compare maternal and paternal genotypes to control subjects’ genotypes and find evidence that the prevalence of the variant allele is higher in parents of case subjects than in population control subjects.

However, there are other analytic options in this case—namely, flexible statistical methods for case-parent trios which can test for parental-genotype effects. These have the advantage of being robust to population-stratification bias and, in some situations, are even more powerful for testing for parental-genotype effects than case-control studies (Starr et al. 2002).

The log-linear model developed by Weinberg et al. and Wilcox et al. can test for parental-genotype and parent-of-origin effects after adjusting for possible case-genotype effects (Weinberg et al. 1998; Wilcox et al. 1998). In principle, this model can also test parental-genotype × case-genotype interactions—which could be relevant;